Novavax Company Profile (NASDAQ:NVAX)

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The firm earned $5.68 million during the quarter, compared to analysts' expectations of $6.17 million. Novavax had a negative net margin of 1,466.36% and a negative return on equity of 787.38%. The business's quarterly revenue was up 34.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.29) earnings per share. View Novavax's Earnings History.

9 equities research analysts have issued 12 month target prices for Novavax's shares. Their predictions range from $1.17 to $25.00. On average, they expect Novavax's share price to reach $5.77 in the next twelve months. View Analyst Ratings for Novavax.

Here are some recent quotes from research analysts about Novavax stock:

• 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (7/26/2017)
• 2. Cantor Fitzgerald analysts commented, "Important RSV vaccine data to be released next Monday. NVAX plans to host a conference call on Monday, July 24, at 4:30pm EDT, on which top-line data from the E-205 Phase 2 clinical trial of the RSV vaccine candidate in older adults will be discussed. The company’s press release notes that an update of the ongoing pivotal Prepare trial of the vaccine candidate in pregnant women will also be provided. Of the two programs, we believe the former is likely to be the greater value creator and, if the data are encouraging, could provide a catalyst for renewed investor interest in the stock." (7/21/2017)
• 3. Chardan Capital analysts commented, "The company is at a pre-commercialization stage, although it does recognize revenue from research and development collaborations. Reported revenue in Q4 was $5.4M, which was inline with consensus." (2/28/2017)

Novavax saw a drop in short interest in July. As of July 14th, there was short interest totalling 54,638,918 shares, a drop of 3.9% from the June 30th total of 56,851,825 shares. Based on an average daily trading volume, of 2,809,930 shares, the short-interest ratio is currently 19.4 days. Currently, 19.6% of the shares of the stock are short sold.

Some companies that are related to Novavax include WAVE Life Sciences (WVE), ANI Pharmaceuticals (ANIP), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), Adamas Pharmaceuticals (ADMS), PDL BioPharma (PDLI), Abeona Therapeutics (ABEO), Concert Pharmaceuticals (CNCE), Celyad SA (CYAD), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Curis (CRIS), Idera Pharmaceuticals (IDRA), Advaxis (ADXS) and Nabriva Therapeutics AG (NBRV).

Novavax's management team includes the folowing people:

• James Francis Young Ph.D., Independent Chairman of the Board
• Stanley C. Erck, President, Chief Executive Officer, Director
• Barclay A. Phillips, Chief Financial Officer, Senior Vice President, Treasurer
• Gregory M. Glenn M.D., President, Research and Development
• John A. Herrmann III, Senior Vice President, General Counsel, Corporate Secretary
• John J. Trizzino, Senior Vice President - Commercial Operations
• James F. Cummings, Vice President - Clinical Development and Translational Medicine
• Rajiv I. Modi Ph.D., Director
• Gail Koziara Boudreaux, Independent Director
• Richard H. Douglas Ph.D., Independent Director

Novavax's stock is owned by a number of of retail and institutional investors. Top institutional investors include Creative Planning (0.17%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.

Novavax's stock was purchased by a variety of institutional investors in the last quarter, including Creative Planning. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.

Shares of Novavax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Novavax stock can currently be purchased for approximately $1.02.